The effects of research and development expense, promotion and distribution expense, training expense, return on equity and gross domestic product on stock return before and during the covid-19: evidence form Indonesian pharmaceutical companies for Q1 201
Total View This Week0
Total View This Week0
Institusion
Sekolah Tinggi Manajemen Ipmi
Author
Sidarta, Anneke
Subject
H Social Sciences (General)
Datestamp
2022-01-24 07:41:34
Abstract :
The need of costs of research and development (R&D), promotion and distribution, training are very crucial for pharmaceutical companies. These costs influence the company's performance that will impact its share return especially if there is an extraordinary condition that emerged from the macro environment, such as the Covid-19 pandemic. The objective of the study will measure and evaluate the impact of these costs, as independent variables toward the share return as the dependent variable. In Kalbe Farma Tbk, the cost of training for Q4 2020 is 163% compared with Q3 2020, however, the share return and income showed inconsistency for this period. The share return is minus five and the return of equity is higher compared with Q3 2020. There were two pharmaceutical companies listed in the Jakarta stock exchange as the objects. The quarterly data are taken from the financial reports Q1 2010 - Q2 2021. The financial reports show that there is a gap between those cost-share returns and income.
The need of costs of research and development (R&D), promotion and distribution, training are very crucial for pharmaceutical companies. These costs influence the company's performance that will impact its share return especially if there is an extraordinary condition that emerged from the macro environment, such as the Covid-19 pandemic. The objective of the study will measure and evaluate the impact of these costs, as independent variables toward the share return as the dependent variable. In Kalbe Farma Tbk, the cost of training for Q4 2020 is 163% compared with Q3 2020, however, the share return and income showed inconsistency for this period. The share return is minus five and the return of equity is higher compared with Q3 2020. There were two pharmaceutical companies listed in the Jakarta stock exchange as the objects. The quarterly data are taken from the financial reports Q1 2010 - Q2 2021. The financial reports show that there is a gap between those cost-share returns and income.
Download
book
BibTex
Latex, Jabref
cloud_download
Original Resource
url resource Institution
